Keywords: Roche, Hercptin injectable, Breast cancer, Ph III, Line extension

Injectable Herceptin set to transform breast cancer care, says Roche

Article | 25 March 2012

Print This

Data from the Phase III HannaH trial presented last Friday at the European Breast Cancer Conference, Vienna, Austria, could mean ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in